688520 神州细胞
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-96.024-419.696-48.82794.728224.112
总资产报酬率 ROA (%)-9.394-15.8933.730-14.521-25.261
投入资产回报率 ROIC (%)-10.932-18.9404.625-18.787-35.586

边际利润分析
销售毛利率 (%)90.30693.09895.91397.11096.689
营业利润率 (%)-48.056-27.96822.6210.337-34.958
息税前利润/营业总收入 (%)-52.051-30.6168.508-15.291-42.225
净利润/营业总收入 (%)-57.204-36.2914.471-21.026-50.827

收益指标分析
经营活动净收益/利润总额(%)81.81291.381442.2805.63675.009
价值变动净收益/利润总额(%)1.426-2.0541.126-0.624-1.174
营业外收支净额/利润总额(%)16.37622.581-405.929101.60431.223

偿债能力分析
流动比率 (X)0.8760.6940.7260.5231.116
速动比率 (X)0.7240.5710.5970.4230.976
资产负债率 (%)83.83996.85395.891122.285108.852
带息债务/全部投入资本 (%)77.25090.84585.421114.83269.035
股东权益/带息债务 (%)24.0004.3136.131-24.270-16.601
股东权益/负债合计 (%)19.0703.4634.474-18.032-7.946
利息保障倍数 (X)-9.611-5.5562.108-2.667-4.908

营运能力分析
应收账款周转天数 (天)139.009137.33773.10860.37460.424
存货周转天数 (天)974.374996.051810.0351,302.1971,496.688